BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla total assets
Total assets on the balance sheet at the end of each period.
BioAtla's total assets was $9.51M at Jun 30, 2026. For fiscal 2025 it was $13.83M, down 73.6% from the year before. The highest annual figure on record is $254.42M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.83M | -73.6% |
| FY2024 | Dec 31, 2024 | $52.42M | -56.2% |
| FY2023 | Dec 31, 2023 | $119.66M | -47.0% |
| FY2022 | Dec 31, 2022 | $225.74M | -11.3% |
| FY2021 | Dec 31, 2021 | $254.42M | +3.9% |
| FY2020 | Dec 31, 2020 | $244.94M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.51M | -65.0% |
| Q1 FY2026 | Mar 31, 2026 | $8.57M | -77.6% |
| Q4 FY2025 | Dec 31, 2025 | $13.83M | -73.6% |
| Q3 FY2025 | Sep 30, 2025 | $15.91M | -74.4% |
| Q2 FY2025 | Jun 30, 2025 | $27.13M | -60.5% |
| Q1 FY2025 | Mar 31, 2025 | $38.29M | -57.1% |
| Q4 FY2024 | Dec 31, 2024 | $52.42M | -56.2% |
| Q3 FY2024 | Sep 30, 2024 | $62.24M | -58.9% |
| Q2 FY2024 | Jun 30, 2024 | $68.64M | -61.8% |
| Q1 FY2024 | Mar 31, 2024 | $89.20M | -56.4% |
| Q4 FY2023 | Dec 31, 2023 | $119.66M | -47.0% |
| Q3 FY2023 | Sep 30, 2023 | $151.36M | -20.0% |
| Q2 FY2023 | Jun 30, 2023 | $179.64M | -15.9% |
| Q1 FY2023 | Mar 31, 2023 | $204.55M | -11.3% |
| Q4 FY2022 | Dec 31, 2022 | $225.74M | -11.3% |
| Q3 FY2022 | Sep 30, 2022 | $189.11M | -31.9% |
| Q2 FY2022 | Jun 30, 2022 | $213.50M | -1.5% |
| Q1 FY2022 | Mar 31, 2022 | $230.65M | +0.7% |
| Q4 FY2021 | Dec 31, 2021 | $254.42M | +3.9% |
| Q3 FY2021 | Sep 30, 2021 | $277.58M | – |
| Q2 FY2021 | Jun 30, 2021 | $216.71M | – |
| Q1 FY2021 | Mar 31, 2021 | $229.09M | – |
| Q4 FY2020 | Dec 31, 2020 | $244.94M | – |
See a number that looks wrong?